Segment 2 - Histology, Targeted Therapy and Surgery

Dr Langer suggests that historically, there’s been a “monolithic approach” to treating NSCLC. “The histologic distinctions have really come to the forefront now in advanced disease, whereas perhaps 8 to 10 years ago it didn’t really make much of a difference,” he says, “so we are holding our pathologists’ ‘feet to the fire.’”

The panel also discusses targeted therapy and surgery in treatment of NSCLC.

Dr Sugarbaker says surgery is dynamic, noting there are a number of techniques to resect or remove the tumor with technology’s help. “These have significantly reduced the morbidity or the stress and pain for the patient.”